CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
CVI Accepts, published online ahead of print on 14 March 2007
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00231-06v1
14/5/562    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herremans, M.
Right arrow Articles by Koopmans, M. P.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herremans, M.
Right arrow Articles by Koopmans, M. P.G.

 Previous Article  |  Next Article 

Clin. Vaccine Immunol. doi:10.1128/CVI.00231-06
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Experience with diagnostic investigations of genotype 1 and genotype 3 hepatitis E patients in a low-endemic setting

M. Herremans*, J. Bakker, E. Duizer, H. Vennema, and M. P.G. Koopmans

National Institute for Public Health and the Environment (RIVM). Diagnostic Laboratory for infectious diseases and perinatal screening

* To whom correspondence should be addressed. Email: Tineke.Herremans{at}rivm.nl.


   Abstract

Because of the occurrence of genotype 3 HEV in the low-endemic regions, it is important to validate the currently used serological assays for diagnosing infections with viruses belonging to this lineage since these assays only use antigens derived from genotype 1 and 2 viruses. We evaluated the Genelabs ELISA and the RecomBlot from Mikrogen for the detection of HEV-specific IgM and IgG under low-endemic conditions. We compared test result of 16 locally acquired genotype 3 HEV patients, 8 genotype 1 patients, 167 healthy controls from the general population and 101 cases with hepatitis due to other viral causes. The measured specificity of the ELISA (98%) and the RecomBlot (97%) were comparable to those given by the manufacturer for IgM but was significantly lower for IgG (93% ELISA and 66% immunoblot, reported 98% ELISA, 95% blot). Antibody levels detected following infections with genotype 3 were lower than those following genotype 1 infections except for those measured in the IgM ELISA. Reactivity to the four antigens used in the immunoblot were analysed and showed differences in the IgM immunoblot reactions between genotype 1 patients, and genotype 3 patients. The ORF3 antigen was the most specific antigen. The specificity could be improved by a combined testing regime with confirmation by immunoblot of all positive ELISA results and by raising the cut-off of the IgG immunoblot without loss of sensitivity. We conclude that a combination of ELISA and immunoblot is needed for acceptable specificity and sensitivity of HEV assays under low-endemic conditions.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.